P077: Subcutaneous fentanyl administration for pain management in prehospital setting

Background: Intravenous (IV) and Intranasal (IN) route for analgesic administration cannot always be used to provide adequate pain management in pre-hospital setting. Objective: In a rural and suburban pre-hospital setting, studying the feasibility, safety and effectiveness of the subcutaneous (SC) route for fentanyl administration by Basic Life Service-Emergency Medical Technician (BLS-EMT) for pain management, with the support of an online medical control (OLMC) center. Methods: Retrospective study of patients who received subcutaneous fentanyl and were transported by BLS-EMT to an emergency department (ED). Safety and feasibility were characterized by collecting vital signs, Ramsey sedation scores and adverse events following fentanyl administration, and effectiveness was evaluated by changes in pain scores. Parametric and non-parametric tests were used for statistical analyses comparing age groups (<70 & ≥70 years old) regarding transport time. Results: Pain scores ≥7 were found in 288 patients (14-93 years old) who were eligible for analgesia. 249 (86.5%) of the 284 (98.6%) who received subcutaneous fentanyl were included for analysis. At baseline, no difference (p>0.05) in pain scores pre-fentanyl between groups even if patients<70 years old received a significant higher dose of fentanyl than those ≥70 years old (1.4±0.3 v/s 0.8±0.2mcg/kg, p<0.05). Post-administration pain score decreased significantly while proportion of patients achieving a pain relief increased significantly (p<0.05) regarding transport time (15, 30 or 45min) to ED. Adverse events were present in 1.6% of the patients [hypotension (n=2; 0.8%), nausea (n=1; 0.4%), and Ramsey score>3 (n=1; 0.4%)]. Conclusion: Under the supervision of an OLMC center, subcutaneous fentanyl administration by BLS-EMT for pain management seems to be a feasible approach, with a safe and effective route without major adverse event in pre-hospital setting. Pain relief increased with longer transport time. Further studies are needed to determine the benefits of SC route when compared to other administration routes in EMS.

Download Full-text

Comparing the efficacy of nebulized morphine with intravenous morphine in traumatic musculoskeletal pain management

Journal of Research in Clinical Medicine ◽

10.34172/jrcm.2020.021 ◽

2020 ◽

Vol 8 (1) ◽

pp. 21-21

Author(s):

Mani Mofidi ◽

Ali Dashti ◽

Mahdi Rezai ◽

Niloufar Ghodrati ◽

Hoorolnesa Ameli ◽

...

Keyword(s):

Pain Management ◽

Pain Relief ◽

Musculoskeletal Pain ◽

Normal Saline ◽

Rating Scale ◽

Numerical Rating Scale ◽

Vital Signs ◽

Categorical Variables ◽

Intravenous Morphine ◽

Numerical Rating

Introduction: This study was designed to compare the effectiveness of intravenous morphine with nebulized morphine in pain relief of patients referring to the emergency setting with traumatic musculoskeletal pain. Methods: This randomized, placebo-controlled and double-blind clinical study evaluated 160 patients 18 to 65 years of age with acute traumatic pain, who attended the emergency department during 2019. Subjects were assessed with Numerical Rating Scale based on inclusion and exclusion criteria and randomly divided into two groups. In one group, 80 patients received IV morphine (0.1 mg/kg+5 mL normal saline) plus an equivalent volume of IV placebo. In the second group, 80 patients received nebulized morphine (0.2 mg/kg+5 mL normal saline) plus nebulized placebo. Pain score was monitored in all patients with Numerical Rating Scale before and after intervention at baseline, 15, 30, 45, and 60-minute intervals. Patients’ vital signs and possible adverse events were evaluated in each observation time points. Finally, all participants were assessed for their satisfaction with pain management. Data were analyzed using repeated measure analysis for continuous variables and Binomial test for categorical variables Results: There was no significant difference between the demographic characteristics of patients in study groups. Pain relief between the two groups was similar during the observation (0, 15, 30, 45, 60 min) (P>0.05). There were no changes in vital signs between two groups, although the nebulized group had lower systolic blood pressure at the time-point of 15 minutes after the treatment initiation (P=0.03). Conclusion: Although Nebulized morphine has similar efficacy in comparison with IV route, nebulization might be considered as the clinically efficacious route of morphine administration with minimal side effects, providing optimal pain relief in patients.

Download Full-text

An Audit of Pain Control Pathways following Video-Assisted Thoracoscopic Surgery

Innovations Technology and Techniques in Cardiothoracic and Vascular Surgery ◽

10.1097/imi.0b013e31822b2cc1 ◽

2011 ◽

Vol 6 (4) ◽

pp. 248-252 ◽

Cited By ~ 5

Author(s):

Espeed Khoshbin ◽

Ali N. Al-Jilaihawi ◽

Nicholas B. Scott ◽

Dhruva Prakash ◽

Alan J. B. Kirk

Keyword(s):

Pain Management ◽

Pain Relief ◽

Visual Analog Scale ◽

Severe Pain ◽

Thoracoscopic Surgery ◽

Analog Scale ◽

Pain Scores ◽

Audit Commission ◽

Video Assisted Thoracoscopic Surgery ◽

Daily Pain

Objective To compare different modes of pain management following video-assisted thoracoscopic surgery (VATS) to our national standard. Methods This is an audit based on patient's experiences. One hundred consecutive patients who underwent VATS with or without pleurodesis were managed by one of the following pain relief pathways: (A) thoracic paravertebral block + morphine patient-controlled analgesia (PCA), (B) percutaneous thoracic paravertebral catheter +/– morphine PCA, (C) thoracic epidural +/– morphine PCA, (D) morphine PCA alone, and (E) intravenous or subcutaneous morphine as required. Pain score was documented up to four times per day for each patient. The incidence of severe pain was defined as visual analog scale ≥7. The results were compared with the standard set by the audit commission for postoperative pain relief in the UK. The mean daily pain scores were calculated retrospectively for all patients. Results There were no statistically significant differences in mean daily pain scores irrespective of having a pleurodesis. The percentage of patients experiencing severe pain was 34% [mean visual analog scale = 8 (standard deviation = 1.0)]. This was almost seven times the standard. Among these pathways, B had the least percentage incidence of severe pain (16.7%) followed by A (25.0%) D (33.3%), C (35.7%), and E (52.4%). Conclusions We are not compliant with the standards set by the audit commission. Pain management in theater recovery needs to be targeted. In the light of these results, we recommend the use of percutaneous thoracic paravertebral catheter +/– morphine PCA for postoperative VATS pain relief.

Download Full-text

127 Impact of CYP2D6, CYP3A4, and CYP2C9 pharmacogenomic profile on pain relief and adverse events in Canadian children treated with oxycodone and ibuprofen

Paediatrics & Child Health ◽

10.1093/pch/pxab061.102 ◽

2021 ◽

Vol 26 (Supplement_1) ◽

pp. e90-e90

Author(s):

Aran Yukseloglu ◽

Samina Ali ◽

Amy Drendel ◽

Bruce Carleton ◽

Colin Ross ◽

...

Keyword(s):

Pain Management ◽

Pain Relief ◽

Adverse Events ◽

Functional Limitations ◽

Clinical Effectiveness ◽

Pediatric Emergency ◽

Pain Scale ◽

Genomic Variation ◽

Children's Pain ◽

Ibuprofen Group

Abstract Primary Subject area Clinical Pharmacology and Toxicology Background Genomic variation impacts drug pharmacokinetics for commonly used children’s pain medications such as oxycodone and ibuprofen. In order to personalize and best treat children’s pain, how cytochrome enzyme polymorphisms for CYP2D6, CYP3A4, and CYP2C9 impact clinical effectiveness and safety for oxycodone and ibuprofen were studied. Objectives Primary objectives were to evaluate if allelic variations of CYP2D6, CYP2C9, and CYP3A4 would a) alter clinical effectiveness of ibuprofen and oxycodone for pain relief, and b) impact the occurrence of adverse events. Secondary objectives were to determine the degree to which these genetic and other clinical factors influence analgesic effectiveness and safety. Design/Methods This prospective, observational cohort included children aged 4-16 years who were seen in a pediatric emergency department (between June 2010 - July 2014) with an acute fracture and used ibuprofen OR oxycodone for at-home pain management. Saliva samples were obtained prior to discharge, and daily telephone follow-up collected self-reported pain scores, medication use, adverse events, and functional limitations for 3 days. Genotyping identified allelic variants of CYP2D6, CYP3A4, and CYP2C9. Pain was measured using the Faces Pain Scale-Revised. CYP2D6 metabolic phenotypes were determined based on identified variants. Regression analyses were employed to determine relationships between clinical and genomic patient characteristics, pain relief, and adverse events. Results We included 210 children (n=140 ibuprofen, n=70 oxycodone); mean age was 11.1 (±3.5) years, 66.2% were male, and 79.5% self-identified as Caucasian. The median pain reduction in the ibuprofen group was 4 (±2.0) and 4 (±3.5) in the oxycodone group on Day 1 (p = 0.69). Adverse events were experienced by 53.2% of the ibuprofen group and 78.3% of the oxycodone group (p < 0.001). CYP2D6 Intermediate Metabolizers had significantly less pain relief using oxycodone than Extensive Metabolizers (p = 0.04). CYP3A4 variants did not significantly impact pain relief or adverse events. Those with the decreased functioning CYP2C9*2 allele experienced less adverse events compared to the normal functioning allele CYP2C9*1 (p = 0.003) when using ibuprofen. Males (p = 0.035) and all children using non-pharmacological pain strategies (p = 0.02) experienced less pain relief with oxycodone. Conclusion A better understanding of pharmacogenomic variation could help personalize medication choice. Sex and non-pharmacologic pain management impact pain relief with oxycodone, warranting further study to better understand their relationship with opioid pain relief in children.

Download Full-text

Perspectives of pain specialists, patients, and family members on long-term opioid use for chronic non-cancer pain: a qualitative study

BMC Anesthesiology ◽

10.1186/s12871-021-01501-8 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Rattaphol Seangrung ◽

Thongchai Tempeetikul ◽

Supasit Pannarunothai ◽

Supalak Sakdanuwatwong

Keyword(s):

Pain Management ◽

Pain Relief ◽

Qualitative Study ◽

Adverse Events ◽

Cancer Pain ◽

Family Members ◽

Opioid Therapy ◽

Functional Improvement ◽

Opioid Use

Abstract Background Opioids are currently prescribed for chronic non-cancer pain (CNCP), and some patients use opioids continuously for long-term treatment. Stakeholders’ awareness about long-term opioid therapy is essential for improving the safety and effectiveness of pain treatment. The purpose of this study is to explore the perspectives of pain specialists, patients, and family caregivers about long-term opioid use in CNCP management. Methods This study was a qualitative study and adhered to the COREQ guidelines. Pain specialists (n = 12), patients (n = 14), and family members (n = 9) were recruited to the study by purposive sampling at the Pain Clinic of Ramathibodi Hospital. Semi-structured interviews were recorded, verbatim transcribed, conceptually coded, and analyzed using Atlas.ti 8.0. Results All groups of participants described opioids as non-first-line drugs for pain management. Opioids should be prescribed only for severe pain, when non-opioid pharmacotherapy and non-pharmacological therapies are not effective. Patients reported that the benefits of opioids were for pain relief, while physicians and most family members highlighted that opioid use should improve functional outcomes. Physicians and family members expressed concerns about opioid-related side effects, harm, and adverse events, while patients did not. Patients confirmed that they would continue using opioids for pain management under supervision. However, physicians stated that they would taper off or discontinue opioid therapy if patients’ pain relief or functional improvement was not achieved. Both patients and family members were willing to consider non-pharmacological therapies if potential benefits existed. Patient education, doctor–patient/family relationships, and opioid prescription policies were proposed to enhance CNCP management. Conclusion Long-term opioid therapy for CNCP may be beneficial in patients who have established realistic treatment goals (for both pain relief and functional improvement) with their physicians. Regular monitoring and evaluation of the risks and benefits, adverse events, and drug-related aberrant behaviors are necessary. Integrated multimodal multidisciplinary therapies and family member collaborations are also important for improving CNCP management.

Download Full-text

Safety and efficacy of single CHAP Hyaluronan injection versus three injections of linear Hyaluronan in pain relief for knee osteoarthritis: a prospective, 52-week follow-up, randomized, evaluator-blinded study

BMC Musculoskeletal Disorders ◽

10.1186/s12891-021-04467-3 ◽

2021 ◽

Vol 22 (1) ◽

Author(s):

Teng-Le Huang ◽

Chun-Hao Tsai

Keyword(s):

Hyaluronic Acid ◽

Pain Relief ◽

Adverse Events ◽

Knee Osteoarthritis ◽

Pain Score ◽

Single Injection ◽

Analysis Of Covariance ◽

Knee Oa ◽

Link Type ◽

Pain Scores

Abstract Background The hyaluronic acid (HA) injections are widely used in knee osteoarthritis (OA) patients. We conducted the study comparing the efficacy and safety of single injection of Crosslinked Hyaluronic Acid Platform Hyaluronan (CHAP-HA) with 3-injection of linear hyaluronan in knee OA patients. Methods This was a randomized two-arms, evaluator-blinded, controlled, single-center study. Participants with knee OA received single CHAP-HA or three-injection of linear-HA. The 140 patients aged 35–85 years with radiographically confirmed knee OA were enrolled. At week 4, 12, 26, 39, and 52, visual analog scale (VAS) pain score, Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index, timed up and go (TUG) and subject’s adverse events (AE) of these 2 groups were recorded. Primary outcome of the differences of VAS pain score at week 26 between groups was analyzed with analysis of covariance (ANCOVA). At week 52, those who met the inclusion criteria could receive a CHAP-HA injection and being followed-up for the adverse events for 4 weeks. Results The trial was conducted from September 2015 to April 2017. A total 140 subjects were available for analysis (71 in the CHAP-HA group and 69 in the linear-HA group). At 26th week, there were significant more improvements in VAS pain scores in CHAP-HA compared with linear-HA. Both CHAP-HA and linear-HA showed significant improvements in the VAS pain score at week 26 compared with the baseline, and the occurrence of adverse events during the study period showed no between-group difference. In subjects with KL = 2, both groups showed significant improvements in VAS pain scores within 26 weeks. In patients with KL = 3, only CHAP-HA group showed significant improvement in VAS pain from 4 to 39 weeks. No unexpected or severe AEs were reported. Conclusions A single injection of CHAP-HA may be safe and more effective for 26 weeks in patients with knee OA by comparing to linear-HA; moreover, the pain relief effect of CHAP-HA may remain until 52 weeks. For patients with more severe OA, CHAP-HA was demonstrated to be more preferable to relieve OA pain. Furthermore, repeat treatment of CHAP-HA or using CHAP-HA after a three-injection HA was proved to be safe. Trial registration ClinicalTrials.gov: NCT03643588. Date: August 23, 2018 (retrospectively registered). Level of Evidence: Therapeutic Level I.

Download Full-text

An opioid-sparing protocol with intravenous parecoxib can effectively reduce morphine consumption after simultaneous bilateral total knee arthroplasty

Scientific Reports ◽

10.1038/s41598-021-86826-7 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Hsuan-Hsiao Ma ◽

Te-Feng Arthur Chou ◽

Hsin-Yi Wang ◽

Shang-Wen Tsai ◽

Cheng-Fong Chen ◽

...

Keyword(s):

Total Knee Arthroplasty ◽

Pain Management ◽

Pain Relief ◽

Adverse Events ◽

Knee Arthroplasty ◽

Bilateral Total Knee Arthroplasty ◽

Morphine Dose ◽

Opioid Dose ◽

Opioid Sparing ◽

Total Knee

AbstractMultimodal pain management protocol effectively relieves pain following simultaneous bilateral total knee arthroplasty (SBTKA) but is associated with administration of large amounts of opioids in the perioperative period. In this prospective, randomized, assessor-blinded, single-surgeon clinical trial, the goal was to validate the efficacy of an opioid-sparing protocol for SBTKA with a reduced opioid dose, while achieving similar pain relief with few adverse events. Fifty-six patients who had undergone SBTKA were randomly allocated to receive either an opioid-sparing or opioid-based protocol. The primary outcome parameters were visual analogue scale (VAS) scores at rest, with movement, and cumulative morphine dose, through time. Secondary outcome parameters included drug-related adverse events and range of motion with continuous passive motion device, through time. In the opioid-sparing group, a lower VAS score with movement at postoperative 24 and 72 h was observed compared with the opioid-based group, but the difference did not reach the minimal clinically importance difference. A reduced cumulative morphine dose was noted in the opioid-sparing group at postoperative 24, 48 and 72 h. In conclusion, the opioid-sparing protocol may be used as an alternative modality for pain management following SBTKA. Similar pain relief effects may be achieved utilizing a reduced cumulative opioid dose, with few opioid related adverse events.

Download Full-text

A Randomized Sequential Allocation Study to Determine the Minimum Effective Analgesic Concentration of Levobupivacaine and Ropivacaine in Patients Receiving Epidural Analgesia for Labor

Anesthesiology ◽

10.1097/00000542-200312000-00022 ◽

2003 ◽

Vol 99 (6) ◽

pp. 1383-1386 ◽

Cited By ~ 60

Author(s):

Dan Benhamou ◽

Caroline Ghosh ◽

Frédéric J. Mercier

Keyword(s):

Adverse Events ◽

Epidural Analgesia ◽

Vital Signs ◽

Sensory Block ◽

Labor Pain ◽

Double Blind Study ◽

Double Blind ◽

Treatment Groups ◽

Pain Scores ◽

Sequential Allocation

Background This study was designed to determine and compare the minimum local analgesic concentrations of levobupivacaine and ropivacaine when used in epidural obstetric analgesia. Methods In a double-blind study, healthy women requiring epidural analgesia for labor pain were randomized to receive either ropivacaine or levobupivacaine. Drugs were administered as a 20-ml epidural bolus. The concentration of each started at 0.11% and increased or decreased at intervals of 0.01%, depending on the response of the previous patient, using the technique of up-down sequential allocation. Minimum local analgesic concentrations were calculated using the formula of Dixon and Massey. Efficacy was assessed using visual analog pain scores and motor and sensory block assessments, and safety was assessed by recording maternal and fetal/neonate vital signs and adverse events. Results Forty-seven patients received levobupivacaine, and 47 received ropivacaine. Minimum local analgesic concentrations for levobupivacaine (0.077%; 95% CI, 0.058-0.096%) were lower than those for ropivacaine (0.092%; 95% CI, 0.082-0.102%). The 0.015% difference was not statistically significant. There was no notable difference between treatment groups in the proportion of patients reporting drug-related adverse events. Conclusions Levobupivacaine was 19% more potent than ropivacaine and provided similar safety results.

Download Full-text

P130: Incidence and characteristics of ventricle fibrillation in patients with ST-elevation myocardial infarction in a suburban pre-hospital setting

CJEM ◽

10.1017/cem.2016.304 ◽

2016 ◽

Vol 18 (S1) ◽

pp. S121-S121

Author(s):

A.B. Tanguay ◽

J. Lebon ◽

F. Bégin

Keyword(s):

Myocardial Infarction ◽

Age Groups ◽

Hospital Setting ◽

St Elevation Myocardial Infarction ◽

Quebec City ◽

Specific Population ◽

Transport Time ◽

Ambulance Transport ◽

St Elevation ◽

Electrocardiogram Ecg

Introduction:Background: Ischemic ventricular fibrillation (VF) is highly related to ST elevation myocardial infarction (STEMI). Pre-hospital STEMI patients have been shown to also develop VF during ambulance transport. However, there is limited literature exploring the characteristics of this specific population of VF. Objective: To determine the incidence of pre-hospital VF, and evaluate some demographic and electrocardiogram (ECG) characteristics of STEMI patients having VF while transported by ambulance in a Quebec suburban pre-hospital setting. Methods: A retrospective study from 8th August 2006 to 6th December 2015 of 937 STEMI patients transported by ambulance in the Chaudiere-Appalaches region, south of Quebec City. Destination for treatment was either Catherization Laboratory (CL) or the nearest Emergency Department (ED) for reperfusion treatment and was mainly based upon a maximum transport time of 60 minutes, from the first confirmed STEMI-ECG to the CL. Demographics and ECG characteristics were extracted from the patients care records. SPSS-20 was used for descriptive statistics. Results: 937 patients (259 women & 678 men) diagnosed with STEMI were included in the study. Patients were regrouped in V1-V4 leads STEMI (336; 35.9%) and in other leads STEMI (651; 64.1%). 52 (5.55%) of all STEMI patients had FV during ambulance transport. There were 10 women (27,4%) and 42 men (72,6%). Of these, 28 had V1-V4 STEMI (28/336; 8.33%) while 24 had other leads STEMI (24/651; 3.69%). Relative risk of FV is higher (225%) with V1-V4 STEMI compared to other leads STEMI. Regarding age groups, patients from 60 to 70 years old represent 38.4% (20/52) of FV for 25.7% (241/937) of STEMI patients while those over 80 years old had 3.85% (2/52) of FV, but were 17% (159/937) of all STEMI patients. Men seem also more at risk for FV (16/20) especially between 60 and 70 years old compare to other age group. Conclusion: In this suburban area, VF occurred in 5.55% of STEMI patient’s transported by ambulance. STEMI patients over 80 years old had a low rate of FV. Being a man, 60 to 70 years old, with a STEMI located in V1-V4, seems to be associated with a higher risk of VF. More studies are needed to confirm these results and explore other characteristics associated to pre-hospital VF.

Download Full-text

Tolerability And Safety Of Urotainer® Polihexanide 0.02% In Long-Term Catheterized Patients: A Prospective Cohort Study

10.21203/rs.2.21999/v1 ◽

2020 ◽

Author(s):

Jürgen Pannek ◽

Karel Everaert ◽

Sandra Möhr ◽

Will Vance ◽

Frank Van der Aa ◽

...

Keyword(s):

Adverse Events ◽

Prospective Observational Study ◽

Bacterial Colonization ◽

Vital Signs ◽

Serious Adverse Event ◽

Pain Scores ◽

Tract Infections ◽

Catheter Irrigation

Abstract Background: In patients with long-term indwelling bladder catheters, bacterial colonization is inevitable, leading to urinary tract infections or encrustations with subsequent catheter blockage. Currently, bladder irrigations are the most frequently used prophylactic means, but the best solution remains yet to be determined. In vitro studies demonstrate that polihexanide is a promising option for catheter irrigation, but no data about safety and tolerability exist. Methods: In a prospective observational study in patients with long-term (> 2 weeks) indwelling bladder catheter, a 0.02% polihexanide solution was used to rinse the catheter on five consecutive days. Adverse events, tolerability and vital signs were assessed before, during, after and at the end of the treatment period. Results: There was no serious adverse event in the study. A total of 28 adverse events (AEs) in 15 (46.88%) participants were experienced. Absolute changes in pain scores were not clinically relevant. No incidences of either flushing or sweating were found during instillation. Bladder spasms during instillation were reported in two cases during a single instillation. Mean pulse rates did not change by more than 3 beats per minute. Mean changes in body temperature did not exceed 0.12 °C. Clinically relevant changes in blood pressure were recorded for 3 patients. Conclusions: This is the first study to demonstrate that a 0.02% polihexanide solution can safely be used for catheter Irrigation.

Download Full-text

Tolerability and Safety of Urotainer® Polihexanide 0.02% in Long-Term Catheterized Patients: A Prospective Cohort Study

10.21203/rs.2.21999/v2 ◽

2020 ◽

Author(s):

Jürgen Pannek ◽

Karel Everaert ◽

Sandra Möhr ◽

Will Vance ◽

Frank Van der Aa ◽

...

Keyword(s):

Adverse Events ◽

Prospective Observational Study ◽

Bacterial Colonization ◽

Vital Signs ◽

Serious Adverse Event ◽

Pain Scores ◽

Tract Infections ◽

Catheter Irrigation

Abstract Background: In patients with long-term indwelling bladder catheters, bacterial colonization is inevitable, leading to urinary tract infections or encrustations with subsequent catheter blockage. Currently, bladder irrigations are the most frequently used prophylactic means, but the best solution remains yet to be determined. In vitro studies demonstrate that polihexanide is a promising option for catheter irrigation, but no data about safety and tolerability exist.Methods: In a prospective observational study in patients with long-term (> 2 weeks) indwelling bladder catheter, a 0.02% polihexanide solution was used to rinse the catheter on five consecutive days. Adverse events, tolerability and vital signs were assessed before, during, after and at the end of the treatment period. Results: There was no serious adverse event in the study. A total of 28 adverse events (AEs) in 15 (46.88%) participants were experienced. Absolute changes in pain scores were not clinically relevant. No incidences of either flushing or sweating were found during instillation. Bladder spasms during instillation were reported in two cases during a single instillation. Mean pulse rates did not change by more than 3 beats per minute. Mean changes in body temperature did not exceed 0.12 °C. Clinically relevant changes in blood pressure were recorded for 3 patients.Conclusions: This is the first study to demonstrate that a 0.02% polihexanide solution can safely be used for catheter irrigation.

Download Full-text